
The global Next-Generation Tumor Genetic Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Next-Generation Tumor Genetic Testing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Next-Generation Tumor Genetic Testing include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Tumor Genetic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Tumor Genetic Testing.
Report Scope
The Next-Generation Tumor Genetic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next-Generation Tumor Genetic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Tumor Genetic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Segment by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing
Segment by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Tumor Genetic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Fluorescence In Situ Hybridization
1.2.3 Polymerase Chain Reaction
1.2.4 Microarray Technology
1.2.5 Serum Proteomics
1.2.6 Nucleic Acid Sequencing
1.3 Market by Application
1.3.1 Global Next-Generation Tumor Genetic Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Speciality Clinics
1.3.4 Research Institutes
1.3.5 Diagnostics Laboratories
1.3.6 Biopharmaceutical Companies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Tumor Genetic Testing Market Perspective (2019-2030)
2.2 Next-Generation Tumor Genetic Testing Growth Trends by Region
2.2.1 Global Next-Generation Tumor Genetic Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next-Generation Tumor Genetic Testing Historic Market Size by Region (2019-2024)
2.2.3 Next-Generation Tumor Genetic Testing Forecasted Market Size by Region (2025-2030)
2.3 Next-Generation Tumor Genetic Testing Market Dynamics
2.3.1 Next-Generation Tumor Genetic Testing Industry Trends
2.3.2 Next-Generation Tumor Genetic Testing Market Drivers
2.3.3 Next-Generation Tumor Genetic Testing Market Challenges
2.3.4 Next-Generation Tumor Genetic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Tumor Genetic Testing Players by Revenue
3.1.1 Global Top Next-Generation Tumor Genetic Testing Players by Revenue (2019-2024)
3.1.2 Global Next-Generation Tumor Genetic Testing Revenue Market Share by Players (2019-2024)
3.2 Global Next-Generation Tumor Genetic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Tumor Genetic Testing Revenue
3.4 Global Next-Generation Tumor Genetic Testing Market Concentration Ratio
3.4.1 Global Next-Generation Tumor Genetic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Tumor Genetic Testing Revenue in 2023
3.5 Next-Generation Tumor Genetic Testing Key Players Head office and Area Served
3.6 Key Players Next-Generation Tumor Genetic Testing Product Solution and Service
3.7 Date of Enter into Next-Generation Tumor Genetic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Tumor Genetic Testing Breakdown Data by Type
4.1 Global Next-Generation Tumor Genetic Testing Historic Market Size by Type (2019-2024)
4.2 Global Next-Generation Tumor Genetic Testing Forecasted Market Size by Type (2025-2030)
5 Next-Generation Tumor Genetic Testing Breakdown Data by Application
5.1 Global Next-Generation Tumor Genetic Testing Historic Market Size by Application (2019-2024)
5.2 Global Next-Generation Tumor Genetic Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next-Generation Tumor Genetic Testing Market Size (2019-2030)
6.2 North America Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next-Generation Tumor Genetic Testing Market Size by Country (2019-2024)
6.4 North America Next-Generation Tumor Genetic Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Tumor Genetic Testing Market Size (2019-2030)
7.2 Europe Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2019-2024)
7.4 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size (2019-2030)
8.2 Asia-Pacific Next-Generation Tumor Genetic Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Tumor Genetic Testing Market Size (2019-2030)
9.2 Latin America Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next-Generation Tumor Genetic Testing Market Size by Country (2019-2024)
9.4 Latin America Next-Generation Tumor Genetic Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size (2019-2030)
10.2 Middle East & Africa Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Devyser
11.1.1 Devyser Company Detail
11.1.2 Devyser Business Overview
11.1.3 Devyser Next-Generation Tumor Genetic Testing Introduction
11.1.4 Devyser Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.1.5 Devyser Recent Development
11.2 Agendia
11.2.1 Agendia Company Detail
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Tumor Genetic Testing Introduction
11.2.4 Agendia Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.2.5 Agendia Recent Development
11.3 Illumina
11.3.1 Illumina Company Detail
11.3.2 Illumina Business Overview
11.3.3 Illumina Next-Generation Tumor Genetic Testing Introduction
11.3.4 Illumina Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.3.5 Illumina Recent Development
11.4 Personal Genome Diagnostics
11.4.1 Personal Genome Diagnostics Company Detail
11.4.2 Personal Genome Diagnostics Business Overview
11.4.3 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Introduction
11.4.4 Personal Genome Diagnostics Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.4.5 Personal Genome Diagnostics Recent Development
11.5 Veracyte
11.5.1 Veracyte Company Detail
11.5.2 Veracyte Business Overview
11.5.3 Veracyte Next-Generation Tumor Genetic Testing Introduction
11.5.4 Veracyte Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.5.5 Veracyte Recent Development
11.6 Pacific Biosciences of California
11.6.1 Pacific Biosciences of California Company Detail
11.6.2 Pacific Biosciences of California Business Overview
11.6.3 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Introduction
11.6.4 Pacific Biosciences of California Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.6.5 Pacific Biosciences of California Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Next-Generation Tumor Genetic Testing Introduction
11.7.4 Qiagen Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.7.5 Qiagen Recent Development
11.8 Agilent Technologies
11.8.1 Agilent Technologies Company Detail
11.8.2 Agilent Technologies Business Overview
11.8.3 Agilent Technologies Next-Generation Tumor Genetic Testing Introduction
11.8.4 Agilent Technologies Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.8.5 Agilent Technologies Recent Development
11.9 Natera
11.9.1 Natera Company Detail
11.9.2 Natera Business Overview
11.9.3 Natera Next-Generation Tumor Genetic Testing Introduction
11.9.4 Natera Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.9.5 Natera Recent Development
11.10 Bio Rad Laboratories
11.10.1 Bio Rad Laboratories Company Detail
11.10.2 Bio Rad Laboratories Business Overview
11.10.3 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Introduction
11.10.4 Bio Rad Laboratories Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.10.5 Bio Rad Laboratories Recent Development
11.11 Myriad Genetics
11.11.1 Myriad Genetics Company Detail
11.11.2 Myriad Genetics Business Overview
11.11.3 Myriad Genetics Next-Generation Tumor Genetic Testing Introduction
11.11.4 Myriad Genetics Revenue in Next-Generation Tumor Genetic Testing Business (2019-2024)
11.11.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Ìý
Ìý
*If Applicable.
